Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | OGA | O60502 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331652 | 0.86 | RAB9A (0.73) | RAB9ANPC1KMT2ACRBNDDB1 | |
| SCHEMBL3895677 | 0.85 | RAB9A (0.72) | RAB9ANPC1KMT2AALDH1A1CRBN | |
| SCHEMBL7326778 | 0.84 | RAB9A (0.71) | RAB9ANPC1KMT2AALDH1A1CRBN | |
| SCHEMBL1938168 | 0.82 | KDM4E (0.59) | RAB9ANPC1KMT2AALDH1A1HRH3 | |
| SCHEMBL64370 | 0.82 | NPC1 (0.71) | RAB9ANPC1KMT2AALDH1A1CRBN | |
| SCHEMBL532001 | 0.82 | RAB9A (0.67) | RAB9ANPC1KMT2ACRBNDDB1 | |
| SCHEMBL18744958 | 0.82 | RAB9A (0.67) | RAB9ANPC1KMT2AALDH1A1CRBN | |
| SCHEMBL5013526 | 0.81 | UBE2T (0.51) | ALDH1A1HRH3ADRA1AKDM4EWNT3A | |
| SCHEMBL16855255 | 0.81 | ALDH1A1 (0.60) | RAB9ANPC1KMT2AALDH1A1CRBN | |
| SCHEMBL5202526 | 0.81 | RAB9A (0.67) | RAB9ANPC1KMT2ACRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624198-B2 | Substituted piperidinyltetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | RAB9A 844/4885NPC1 846/4885KMT2A 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.